特泽佩umab可改善严重难治性哮喘和鼻窦炎：病例系列
Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series.
作者信息
Inoue Shigesato, Ogata Hiroaki, Dotake Yoichi, Takagi Koichi, Shiota Ayaka, Ishii Yumiko, Tanaka Kentaro, Kan-O Keiko, Inoue Hiromasa
机构信息
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Respiratory Medicine, National Hospital Organization Fukuokahigashi Medical Center, Koga, Fukuoka, Japan.
出版信息
J Allergy Clin Immunol Glob. 2025 Mar 8;4(2):100448. doi: 10.1016/j.jacig.2025.100448. eCollection 2025 May.
Tezepelumab, a mAb targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations in severe asthma. Four cases in which patients with severe asthma and chronic rhinosinusitis with nasal polyps showed improvements in both conditions after receiving tezepelumab treatment are presented.
tezepelumab是一种靶向胸腺基质淋巴细胞生成素（TSLP）的单克隆抗体，可减少重度哮喘的发作。本文介绍了4例重度哮喘合并慢性鼻-鼻窦炎伴鼻息肉患者在接受tezepelumab治疗后，两种疾病均得到改善的病例。
Zotero 插件